Publications by authors named "Jennifer A Roth"

Claim this Profile
T
Tegavivint triggers TECR-dependent nonapoptotic cancer cell death.
Logan Leak, Ziwei Wang, Alby J Joseph, Brianna Johnson, Alyssa A Chan, Jennifer A Roth

Nat Chem Biol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.
Linjie Yuan, Wenzhi Ji, Brendan G Dwyer, Joey Lu, Jing Bian, Jennifer A Roth

Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Biological Evaluation of Colibactin Derivatives.
Yougant Airan, Olga Fedorova, Collin Heer, Matthew G Rees, Melissa M Ronan, Jennifer A Roth

ACS Chem Biol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Mona Foth, Wontak Kim, Kayla T O'Toole, Brandon Murphy, Montserrat Justo-Garrido, Jennifer A Roth

bioRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generative Design of Cell Type-Specific RNA Splicing Elements for Programmable Gene Regulation.
Xi Dawn Chen, Maile Jim, Mounica Vallurupalli, Kai Cao, Andrea Navarro Torres, Jennifer A Roth

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer.
Jie Luo, Zhixiang Chen, Yuanyuan Qiao, Jean Ching-Yi Tien, Eleanor Young, Jennifer A Roth

Nat Genet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity.
Linhui Cao, Jing Yang, Yuhang Liu, Xiaotong Chen, Yufang Shi, Jennifer A Roth

Adv Sci (Weinh)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kα inhibitor and degrader inavolisib can co-opt FGFR2 to enhance responses in patients with PIK3CA-mutated solid tumors and in preclinical models.
Dejan Juric, Kyung Song, Radia M Johnson, Melissa K Accordino, Philippe L Bedard, Jennifer A Roth

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.
Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, Benson S Chellakkan, Fredrik I Thege, Jennifer A Roth, Dorothea Rudolph

Sci Transl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming rapaprotin resistance through inhibition of P-glycoprotein.
Qian Zhang, Thomas Asbell, A V Subba Rao, Kalyan Kumar Pasunooti, Jian Zhang, Jennifer A Roth

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Linda Julian, Lisa Crozier, Devon Lukow, Sanat Mishra, Aditi Swamy, Jennifer A Roth

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of chromatin-based determinants of azacytidine and decitabine anti-cancer activity.
Rishi V Puram, Qiangzong Yin, YuhJong Liu, Justine C Rutter, Daniel Bondeson, Jennifer A Roth

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly specific intracellular ubiquitination of a small molecule.
Weicheng Li, Enrique M Garcia-Rivera, Dylan C Mitchell, Joel M Chick, Micah Maetani, Jennifer A Roth

Nat Chem Biol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate.
Charles Chidi Okechukwu, Xue Ma, Wencheng Li, Ralph D'Agostino, Matthew G Rees, Jennifer A Roth

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The contribution of cyclic imide stereoisomers on cereblon-dependent activity.
Yuka Amako, Saki Ichikawa, Hannah C Lloyd, N Connor Payne, Zhi Lin, Jennifer A Roth

Chem Sci· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage.
Zheqi Li, Guillermo Peluffo, Laura E Stevens, Xintao Qiu, Marco Seehawer, Jennifer A Roth

Nat Genet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation-inducing chimera rewires oncogenic kinase to trigger apoptosis.
Manuel L Merz, Veronika M Shoba, Rajaiah Pergu, Zachary C Severance, Dhanushka N P Munkanatta Godage, Jennifer A Roth

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.
Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner, Jennifer A Roth, Dorothea Rudolph

Mol Cancer Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted degradation of CDK9 potently disrupts the MYC-regulated network.
Mohammed A Toure, Keisuke Motoyama, Yichen Xiang, Julie Urgiles, Florian Kabinger, Jennifer A Roth

Cell Chem Biol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Selective Anticancer Agent from a Collection of Complex-And-Diverse Compounds Synthesized from Stevioside.
Rachel E Schaaf, Jonathan C K Quirke, Maryam Ghavami, Emily J Tonogai, Hyang Yeon Lee, Jennifer A Roth, Paul J Hergenrother

J Am Chem Soc· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers.
Brian Belmontes, Katherine K Slemmons, Chun Su, Siyuan Liu, Antonia N Policheni, Jennifer A Roth

Cancer Discov· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
Julien Dilly, Megan T Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Jennifer A Roth

Cancer Discov· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards, Jennifer A Roth

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
Eric D Huseman, Anna Lo, Olga Fedorova, James L Elia, Susan E Gueble, Jennifer A Roth

J Am Chem Soc· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network.
Mohammed A Toure, Keisuke Motoyama, Yichen Xiang, Julie Urgiles, Florian Kabinger, Jennifer A Roth

bioRxiv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis